Palmoplantar keratoderma, epidermolytic, 2

disease
On this page

Summary

Palmoplantar keratoderma, epidermolytic, 2 (MONDO:0957303) is a disease with 1 cohort gene.

At a glance

  • Cohort genes: 1
  • ClinVar variants: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namepalmoplantar keratoderma, epidermolytic, 2
Mondo IDMONDO:0957303
OMIM620411
DOIDDOID:0070551
UMLSC2936837
MedGen445412
GARD0026814
Is cancer (heuristic)no

Data availability: 4 ClinVar variants.

Disease family

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorderkeratosispalmoplantar keratosishereditary palmoplantar keratodermapalmoplantar keratoderma, epidermolyticpalmoplantar keratoderma, epidermolytic, 2

Related subtypes (1): epidermolytic palmoplantar keratoderma, 1

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

4 retrieved; paginated sample, class counts are floors:

2 uncertain significance, 1 pathogenic, 1 pathogenic/likely pathogenic

ClinVarVariant (HGVS)GeneClassificationReview
66619NM_006121.4(KRT1):c.1254+1G>AKRT1Pathogeniccriteria provided, single submitter
66650NM_006121.4(KRT1):c.563A>G (p.Asn188Ser)KRT1Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
2285008NM_006121.4(KRT1):c.568C>A (p.Gln190Lys)KRT1Uncertain significancecriteria provided, multiple submitters, no conflicts
2433262NM_006121.4(KRT1):c.1307C>A (p.Ala436Asp)KRT1Uncertain significancecriteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 8 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
KRT1Orphanet:2199Epidermolytic palmoplantar keratoderma
KRT1Orphanet:281139Annular epidermolytic ichthyosis
KRT1Orphanet:281190Congenital reticular ichthyosiform erythroderma
KRT1Orphanet:312Autosomal dominant epidermolytic ichthyosis
KRT1Orphanet:50942Striate palmoplantar keratoderma
KRT1Orphanet:530838KRT1-related diffuse nonepidermolytic keratoderma
KRT1Orphanet:538574Palmoplantar keratoderma-hereditary motor and sensory neuropathy syndrome
KRT1Orphanet:79503Ichthyosis hystrix of Curth-Macklin

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

SubsetGenes
multi_evidence1

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
KRT1HGNC:6412ENSG00000167768P04264Keratin, type II cytoskeletal 1clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
KRT1Keratin, type II cytoskeletal 1May regulate the activity of kinases such as PKC and SRC via binding to integrin beta-1 (ITB1) and the receptor of activated protein C kinase 1 (RACK1).

Protein-family classification

Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Other/Unknown11.8×0.558

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
KRT1Other/UnknownnoKeratin_II, IF_conserved, Keratin_2_head

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)1
unknown0

Top tissues across cohort

TissueCohort genes
mammalian vulva1
skin of hip1
upper leg skin1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
KRT1177tissue_specificmarkermammalian vulva, upper leg skin, skin of hip

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
KRT12,716

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
KRT1P042643

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 10. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Regulation of FXIIa and plasma kallikrein activity11142.0×0.009KRT1
Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin1278.5×0.014KRT1
Developmental Cell Lineages1223.9×0.014KRT1
FXIIa activates plasma kallikrein-kinin system1173.0×0.014KRT1
Formation of the cornified envelope187.8×0.023KRT1
Keratinization155.7×0.030KRT1
Innate Immune System125.5×0.054KRT1
Neutrophil degranulation123.1×0.054KRT1
Developmental Biology114.5×0.077KRT1
Immune System113.0×0.077KRT1

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
complement activation, lectin pathway11685.2×0.003KRT1
protein heterotetramerization11053.2×0.003KRT1
cornification11053.2×0.003KRT1
fibrinolysis1842.6×0.003KRT1
establishment of skin barrier1455.5×0.004KRT1
regulation of angiogenesis1421.3×0.004KRT1
intermediate filament organization1240.7×0.005KRT1
keratinization1234.1×0.005KRT1
negative regulation of inflammatory response1137.0×0.008KRT1
response to oxidative stress1130.6×0.008KRT1

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 0 of 1 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

SymbolMoleculesMax phase
KRT100

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)0
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug1KRT1

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
KRT10

Clinical trials & evidence

Clinical trials

Clinical trials: 0.